跳至主要内容
临床试验/NCT04054401
NCT04054401招募中不适用

SynerFuse Spinal Fusion and Neuromodulation Proof of Concept Study

SynerFuse, Inc2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2022年1月6日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
20
试验地点
2
主要终点
Primary Safety Endpoint: Characterization of device-related adverse events

研究概览

简要总结

The purpose of the study is to evaluate the safety and tolerability of DRG stimulation when placing a neurostimulator during the same procedure as implantation of spinal fixation with or without interbody cage systems in patients with chronic back and/or leg pain requiring single level spinal fusion.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
21 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Indicated for a single level or two level adjacent spinal fusion having back pain and radiculopathy
  • •Have been diagnosed with chronic, intractable pain of the lower back and/or leg refractory to conservative therapy for at least 3 of months
  • •At least 6 months since last surgical procedure on the spine
  • •Be 21 years of age or older at the time of enrollment
  • •Be willing and capable of giving informed consent
  • •Be willing and able to comply with study-related requirements

排除标准

  • •Any prior spinal fusion at index or adjacent level
  • •Have a life expectancy of less than 1 year
  • •Be concomitantly participating in another clinical study
  • •Be involved in an injury claim under current litigation
  • •Baseline narcotic use of ≥ 100 MME per day
  • •Significant untreated addiction to dependency producing medications
  • •Current active implantable medical device
  • •Have osteoporosis
  • •Active infection
  • •Allergies to system components
  • •AGE > 80
  • •Expected need to undergo MRI imaging in the future
  • •Other significant comorbidities

研究组 & 干预措施

DRG Neurostimulation with Spinal Fusion

Experimental

干预措施: DRG Neurostimulation with Spinal Fusion (Device)

结局指标

主要结局

Primary Safety Endpoint: Characterization of device-related adverse events

时间窗: Surgery through 12 months post-op

Primary Effectiveness Endpoint: Change in back and leg pain Visual Analog Score (VAS) scores

时间窗: Baseline to 3 months post-op

VAS scores range from 0 (no pain) to 100 (pain is as bad as it could possibly be). Decreases in scores indicate reductions in pain.

次要结局

  • Change in quality of life as measured by EQ-5D-5L.(Baseline to 3, 6, and 12 months post-op)
  • Change in neurological status(Baseline to 3, 6, and 12 months post-op)
  • Change in quality of life as measured by PROMIS Scale v1.2 - Global Health.(Baseline to 3, 6, and 12 months post-op)
  • Change in disability measured by the Oswestry Disability Index (ODI).(Baseline to 3, 6, and 12 months post-op)
  • Change in use of analgesics over time(Baseline through 12 months post-op)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

SynerFuse Spinal Fusion and Neuromodulation Proof of... | 临床试验